Metformin for Longevity: What the Trials Show and Why Healthy People Are Not Prescribed It

The clip runs 38 seconds. A fit man in his sixties holds up a pill bottle, says the word “metformin,” and tells several million viewers that a drug for type 2 diabetes is quietly the best anti-aging tool on earth. The comments fill with the same question: how do I get it? As of early 2026, searches for metformin longevity have climbed on the back of a 2024 study in elderly monkeys and a decade-old British database analysis that keeps resurfacing with a startling headline about people with diabetes outliving people without it.

The science behind the clip is real. So are the gaps in it. Metformin has been used since 1958 and prescribed to hundreds of millions of people, and it remains one of the most carefully studied medicines in existence. That is exactly why its longevity story deserves a slower reading than a social feed allows.

Here is what the trials show, what they do not, and why your physician will almost certainly not write a prescription for a healthy adult who simply wants to age well.

Why metformin longevity is suddenly everywhere

Three things collided. First, a research group in China published results in September 2024 showing that elderly male monkeys given metformin daily for about 40 months aged more slowly on several biological clocks, with brain tissue that looked roughly six years younger than expected. Second, the long-planned TAME trial, designed to test whether metformin delays age-related disease in older adults, keeps appearing in interviews as the study that could change how medicine treats aging itself. Third, a 2014 analysis of UK primary care records, which found that people with diabetes taking metformin had slightly lower mortality than matched people without diabetes, was rediscovered by influencers and condensed into a single viral sentence.

Each ingredient is legitimate. Put together without context, they create an impression the evidence does not support: that a cheap, familiar pill is already proven to extend human life.

The appeal is understandable. Metformin is not a research chemical sold in gray-market vials. It has a 60-year safety record, a well-understood side-effect profile and a plausible mechanism that touches the same cellular pathways that caloric restriction activates in laboratory animals. In the longevity world, that combination is rare. Most interventions with dramatic animal results, such as rapamycin or experimental peptides, carry heavier unknowns in humans.

What the trend leaves out is the difference between a drug that is safe for the people who need it and a drug that benefits people who do not. Those are separate questions, and only the first one has been answered.

What changed recently in the metformin longevity debate

A short timeline helps separate old news from new. In 1998, the UK Prospective Diabetes Study reported that overweight adults with type 2 diabetes assigned to metformin had about 36 percent lower all-cause mortality over roughly a decade than those managed with diet alone. That randomized finding remains the strongest human evidence that metformin helps people live longer, and it applies specifically to people with diabetes.

In 2014, researchers using UK primary care data compared about 78,000 metformin users with matched people without diabetes and reported roughly 15 percent lower mortality in the metformin group. That paper, indexed on PubMed, is the source of nearly every “outlive non-diabetics” claim online.

In 2016, a group of aging researchers published a proposal in Cell Metabolism for the Targeting Aging with Metformin trial, or TAME, and secured agreement from US regulators that a composite of age-related diseases could serve as a trial endpoint. That was a regulatory first.

In 2021, Harvard Health reviewed the state of play and concluded that metformin was promising but unproven for longevity in people without diabetes. In 2022, a reanalysis of the same British database used in 2014, this time correcting for a statistical problem called immortal time bias, found the survival advantage over non-diabetic people disappeared.

Then came the September 2024 monkey study, with 12 elderly male animals and no survival endpoint. As of early 2026, TAME has still not completed enrollment because its funding remains incomplete. So the newest human randomized evidence on metformin and aging is, in effect, still the 1998 study.

How metformin works in the body

Metformin descends from a compound found in French lilac, a plant used for centuries to ease the excessive urination of what we now call diabetes. The modern drug does several things at once, which is part of why it attracts aging researchers.

Its main job is in the liver. Metformin reduces gluconeogenesis, the liver’s production of new glucose from other molecules, so less sugar is released into the bloodstream overnight and between meals. It also makes muscle and fat cells somewhat more responsive to insulin, the hormone that moves glucose out of the blood and into cells.

At the cellular level, metformin mildly dampens one of the energy-generating complexes inside mitochondria, the structures that power cells. The cell senses a slight energy shortfall and switches on an enzyme called AMPK, which acts like a thrift mode: it slows building projects, encourages recycling of damaged components and reduces inflammatory signaling. That same thrift mode is turned on by fasting and caloric restriction, interventions that extend lifespan in worms, flies and mice.

The gut matters too. Metformin changes the bacterial mix in the intestine and increases release of GLP-1, a hormone that slows stomach emptying and signals fullness. Those gut effects help explain both its modest weight-neutral or weight-lowering tendency and its most common side effect, loose stools.

Unlike many diabetes medicines, metformin does not push the pancreas to make more insulin, so on its own it rarely causes dangerously low blood sugar. That favorable profile is why it sits at the front of most treatment guidelines for type 2 diabetes.

Where the "people on metformin outlive non-diabetics" claim came from

The sentence is quoted so often it feels like settled fact. It traces to one observational study, and the study has a problem that its own authors acknowledged.

In 2014, a team using the UK Clinical Practice Research Datalink compared people with type 2 diabetes who had just started metformin with people who had no diabetes at all, matched for age, sex, smoking and other factors. Over a median follow-up of a few years, the metformin group had about 15 percent lower all-cause mortality than the non-diabetic comparison group. The result was genuinely surprising, because diabetes normally shortens life expectancy.

Two features of the design inflate the result. People are started on metformin only when their kidneys and liver are healthy enough to take it, so the metformin group began the study already filtered for good organ function. More importantly, the analysis counted time from diagnosis in a way that gave metformin users a stretch of “immortal” follow-up during which, by definition, they could not have died, because they were still alive to receive the prescription. Statisticians call this immortal time bias. It systematically flatters whichever group has the delayed start.

When another team reanalyzed similar records in 2022 with that bias corrected, the survival advantage over people without diabetes vanished. Metformin users still did better than people on some other diabetes drugs, which is consistent with the randomized trial evidence, but they did not out-survive healthy people.

None of this makes the 2014 paper bad science. It makes it an observational study, which can raise a question but cannot answer it.

What the evidence actually says, graded by strength

Medicine ranks evidence on a ladder. Randomized controlled trials, where participants are assigned by chance to drug or placebo, sit near the top because they cancel out hidden differences between groups. Observational studies, which watch what happens to people who already take a drug, sit lower. Animal and cell studies sit lower still for predicting human outcomes. Here is where each metformin longevity claim lands.

Claim	Best evidence	Strength	What it shows
Lowers mortality in type 2 diabetes	UKPDS randomized trial, 1998, plus decades of follow-up	Strong	About 36 percent lower all-cause mortality vs diet alone in overweight adults with diabetes
Prevents or delays type 2 diabetes in people at high risk	Diabetes Prevention Program, randomized	Strong for diabetes onset	Cut progression by 31 percent over three years; lifestyle change cut it by 58 percent
People on metformin outlive non-diabetics	2014 UK database study	Weak, contradicted	Advantage disappears when immortal time bias is corrected
Reduces cancer in people without diabetes	Randomized add-on trials, including a large breast cancer trial reported in 2022	Negative so far	No improvement in cancer outcomes when added to standard treatment
Slows biological aging in healthy humans	No completed randomized trial	Absent	TAME designed to test this; not yet reported
Extends lifespan in animals	Mice, worms, 2024 monkey study	Suggestive, inconsistent	Benefit varies by species, sex and dose; monkey study measured aging markers, not survival

The honest summary: the top of the ladder supports metformin for people with diabetes or at high risk of it. For everyone else, the human evidence is a mix of biased observational signals, negative randomized add-on trials and a promising but unfinished study.

Does metformin slow aging in people without diabetes? The TAME trial explained

TAME stands for Targeting Aging with Metformin. It is the study that would settle this question, and it is worth understanding why it exists and why it has taken so long.

The design calls for roughly 3,000 adults aged 65 to 79 who do not have diabetes, randomly assigned to metformin or placebo and followed for about six years. Instead of measuring a single disease, the primary outcome is a composite: time until a participant develops any one of several major age-related conditions, including heart disease, cancer, dementia or death. The logic is that a drug acting on aging itself should delay all of these at once, which no disease-specific trial could capture.

In 2016 the researchers published their rationale in Cell Metabolism and, in meetings with US regulators, obtained agreement that this composite endpoint would be acceptable. That mattered enormously. Aging is not an officially recognized disease, so no company could seek approval for an anti-aging indication without a path like this.

The hurdle has been money. Metformin is a generic medicine with no patent to protect, so no manufacturer stands to profit from a six-year trial. Funding has come piecemeal from foundations and public grants, and as of early 2026 enrollment is not complete. Smaller pilot studies have tested metformin’s effects on markers of inflammation and aging in older adults without diabetes, with mixed and modest results.

Until TAME or a similar trial reports, the question in this section’s heading has one accurate answer: nobody knows. That is not a dodge. It is the finding.

Metformin for non-diabetics: why healthy people are not prescribed it

Doctors can legally prescribe any approved medicine for any purpose, a practice called off-label use. So why does a healthy 50-year-old who asks for metformin usually leave empty-handed?

Prescribing rests on a risk-benefit calculation. For a person with type 2 diabetes, the benefit side is loaded with decades of randomized trial data showing fewer heart attacks and deaths. The risk side holds mostly digestive upset, a slow drain on vitamin B12 and a rare but serious complication called lactic acidosis. The balance tips clearly toward treatment.

For a healthy adult, the benefit side is nearly empty. There is no randomized evidence of longer life, better cognition or fewer cancers. The risk side is unchanged. Every stomach cramp, every B12 level that needs monitoring, every blood test is a cost paid against a benefit that may not exist. Guideline bodies, from the NHS to US professional societies, list metformin for diabetes, prediabetes in selected high-risk adults, and, with weaker evidence, polycystic ovary syndrome. Aging is not on the list.

There is also a subtler concern. Several small randomized studies in older adults found that metformin blunted some of the fitness and muscle gains from aerobic and resistance exercise, apparently by damping the same mitochondrial stress signals that training uses to build adaptation. The effect was partial, not total, but it raises the possibility that in an already healthy, active person the drug could trade a hypothetical benefit for a measurable one.

A clinician who declines to prescribe metformin for longevity is not being cautious for its own sake. They are following the evidence to where it currently stops.

Why do I feel so much better on metformin?

This question comes almost entirely from people who were prescribed metformin for a medical reason, and their experience is real. The explanation says a lot about what the drug is and is not doing.

High blood sugar is tiring. Glucose that cannot enter cells efficiently leaves muscles underfueled while the kidneys work overtime to excrete the excess, pulling water with it. People with newly diagnosed or poorly controlled diabetes often describe fatigue, thirst, blurred vision and frequent nighttime urination without connecting these to their blood sugar. When metformin brings glucose down over a few weeks, that fog lifts. The feeling of renewed energy is the removal of a burden, not the addition of a boost.

Some people also notice steadier appetite and fewer afternoon crashes. That fits metformin’s gut effects: slower stomach emptying and higher GLP-1 signaling smooth out the spikes and dips that drive cravings. Modest weight change, typically a few pounds, can follow.

For people with polycystic ovary syndrome, where insulin resistance drives irregular cycles and other symptoms, improved insulin sensitivity can translate into feeling more like oneself.

What this does not tell us is whether a person with normal blood sugar would feel anything at all. There is no excess glucose to clear. Small trials in healthy volunteers tend to report either no subjective change or the opposite, with nausea and loose stools in the first weeks. The “I feel amazing” testimonials circulating online overwhelmingly come from people whose metabolism needed the help. That is a success story for diabetes treatment, not evidence for anti-aging.

Do people on metformin look younger?

Search this phrase and you will find before-and-after photographs, usually of people who also lost weight, started exercising or began treating a condition that had been draining them. Separating the drug from everything else is impossible in a photo.

Here is what can be said with evidence. The 2024 monkey study measured epigenetic clocks, laboratory tests that estimate biological age from chemical tags on DNA, and found metformin-treated animals scored younger in several tissues. Skin was among the tissues sampled, and the drug appeared to reduce some markers of cellular senescence, the state in which old cells stop dividing but keep releasing inflammatory signals. That is a genuine biological finding in 12 male animals over three years. It is not a human result, and a younger epigenetic score is not the same as a younger face.

In people with diabetes, better glucose control does protect skin and small blood vessels over time. Chronically high sugar glues onto proteins such as collagen, a process called glycation that stiffens tissue and contributes to the dulling, sagging quality of skin in long-standing diabetes. Reducing that exposure plausibly helps appearance, but the credit goes to glucose control, which many treatments achieve.

No randomized trial in people without diabetes has measured skin aging, wrinkle depth or any visual outcome on metformin. One mechanism cuts the other way: the drug lowers vitamin B12 absorption, and B12 deficiency can cause pallor, hair changes and a sore, smooth tongue.

Looking younger is a reasonable thing to want. The evidence simply does not place metformin on the list of things known to deliver it.

Which organ is metformin hard on?

The most common answer online is “the kidneys” or “the liver,” and both are slightly wrong in an instructive way.

Metformin is not broken down by the liver. It passes through the body largely unchanged and is removed by the kidneys. The drug does not damage kidneys, but if the kidneys are already weak, metformin accumulates, and that accumulation is what raises the risk of lactic acidosis. Lactic acidosis is a dangerous buildup of lactic acid in the blood that can occur when tissues are starved of oxygen or when the body cannot clear acid normally. It is rare, on the order of a handful of cases per 100,000 patient-years, and most cases occur in people with severe kidney impairment, acute illness, dehydration or heavy alcohol use. This is why clinicians check kidney function before prescribing and periodically afterward, and why metformin is usually paused around surgery, contrast dye scans or serious vomiting and diarrhea.

The liver matters for a different reason. Because the liver clears lactate, significant liver disease is another situation where metformin is used cautiously or avoided, not because the drug harms the liver but because a struggling liver cannot keep pace.

The organ that actually complains most is the gut. Up to a quarter of people experience nausea, cramping, bloating or diarrhea when starting, which usually eases within weeks and is reduced by taking the medicine with food and by extended-release formulations.

So the precise answer is: metformin is hard on the stomach and bowel at first, and it depends on healthy kidneys and liver to stay safe. People with those organs in good shape tolerate it for decades.

Metformin side effects long term: what decades of use have taught us

Few medicines have a longer track record. The pattern of long-term effects is well mapped, which is useful both for people who take metformin and for anyone weighing the longevity hype.

Vitamin B12 is the headline issue. Metformin interferes with the calcium-dependent step that absorbs B12 in the small intestine. Observational studies find lower B12 levels in a meaningful share of long-term users, with risk rising alongside duration and dose. Deficiency develops slowly and can mimic diabetic nerve damage, producing numbness, tingling, balance problems and fatigue, as well as anemia and mood or memory changes. The NIH Office of Dietary Supplements and US diabetes guidelines both recommend periodic B12 testing for people on metformin, especially those with anemia or nerve symptoms. Deficiency is readily corrected under medical guidance.

Digestive symptoms, discussed above, are mostly an early phenomenon, although a minority of people never fully adapt. A persistent metallic taste is reported by some users.

Lactic acidosis remains rare throughout long-term use as long as kidney function is monitored and the drug is paused during acute illness.

On the reassuring side, metformin does not cause weight gain, does not cause low blood sugar on its own and has not been linked to heart failure, fractures or cancer in long-term studies. Its cardiovascular record in people with diabetes is favorable.

The exercise interaction deserves a mention here because it is the one long-term question most relevant to healthy adults. Blunted training adaptation has been seen in small randomized trials over several months. Whether it changes outcomes over years is unknown.

Common myths about metformin anti aging

Viral claims tend to travel further than their corrections. These are the ones worth setting straight.

“Metformin is proven to extend human life.” No randomized trial in people without diabetes has tested lifespan or found it extended. The strong mortality data come from people with type 2 diabetes, in whom the drug treats a disease that shortens life.

“People on metformin live longer than people without diabetes.” This came from one 2014 observational study with immortal time bias. A 2022 reanalysis correcting that bias found no advantage over healthy people.

“It worked in monkeys, so it works in us.” The 2024 study involved 12 elderly male monkeys, measured aging markers rather than survival, and had no female animals. Primate data are more relevant than mouse data, but they are a reason to run human trials, not a substitute for them.

“Metformin prevents cancer.” Early observational studies suggested lower cancer rates in metformin users, but randomized trials adding metformin to standard cancer treatment, including a large breast cancer trial reported in 2022, found no benefit. The observational signal likely reflected who gets prescribed metformin rather than what it does.

“It’s completely harmless, so why not take it?” Metformin is safe for the people who need it, under monitoring. It still carries B12 depletion, gut effects, a rare serious complication and a possible blunting of exercise gains.

“If I can’t get a prescription I can order it online.” Unregulated sellers cannot guarantee what is in the product, and taking a prescription medicine without kidney function checks removes the very safeguard that keeps it safe. This is not a path any evidence supports.

Can you stay on metformin for life?

For people with type 2 diabetes, the answer from decades of practice is often yes, as long as kidney function allows. Many people take metformin for 20 or 30 years. There is no built-in time limit, no tolerance that makes it stop working, and no withdrawal when it is stopped, although blood sugar will typically rise again.

What changes over a lifetime is the body around the drug. Kidney function declines gradually with age and faster with diabetes, so the question clinicians revisit is not “has the patient been on it too long” but “are the kidneys still clearing it well.” Guidelines set thresholds of kidney function at which the dose is reduced and, lower still, at which metformin is stopped. Those thresholds are the reason regular blood tests continue indefinitely.

B12 monitoring also continues for the duration, since deficiency risk accumulates with years of use.

Life events prompt temporary pauses rather than permanent stops: surgery under general anesthesia, imaging with iodinated contrast dye, hospital admission for serious infection, or any illness causing significant dehydration. Once the acute situation resolves and kidney function is confirmed, the medicine is usually resumed. These decisions sit with the treating team, and people are advised never to stop or restart on their own.

For people without diabetes who imagine starting metformin in midlife and continuing for 40 years, there is simply no data. TAME, if completed, will follow participants for about six years. Whether lifelong use in healthy people is helpful, neutral or harmful is a question no study has been designed to answer.

When to see a doctor

Two groups need different guidance: people taking metformin for a medical condition, and people considering it for longevity.

If you take metformin, seek urgent medical care, by calling emergency services if necessary, for any of the following, because they can signal lactic acidosis: unusually rapid or deep breathing, severe muscle pain or cramping, unexplained stomach pain with vomiting, extreme drowsiness or weakness, feeling unusually cold, or a slow or irregular heartbeat. These symptoms are rare but require same-day evaluation.

Contact your prescribing clinician promptly, not urgently, if you develop persistent numbness or tingling in the hands or feet, worsening balance, unexplained fatigue, pallor, a sore or smooth tongue, or new memory and mood changes. These can indicate vitamin B12 deficiency and are checked with a simple blood test. Also tell your clinician before any planned surgery or contrast scan, and if you are vomiting, have diarrhea or cannot keep fluids down for more than a day, since metformin may need to be paused.

Digestive upset that has not settled after the first several weeks, or that interferes with eating, is worth a conversation; formulation or timing changes often help.

If you do not have diabetes and are drawn to metformin for anti-aging, book an ordinary appointment and raise it directly. A good clinician will not dismiss the question. They can check your actual metabolic risk with a fasting glucose or hemoglobin A1c test, a measure of average blood sugar over about three months, and tell you honestly whether you fall into a group for whom the evidence supports treatment. Never start, stop or adjust any prescription medicine without that conversation. The decision belongs to you and your treating physician together, informed by where the evidence currently stands.

Frequently asked questions

Does metformin slow aging in humans?

There is no completed randomized trial showing that metformin slows aging in people without diabetes. The idea rests on animal studies, cellular pathways shared with caloric restriction, and observational data from people with diabetes. The TAME trial was designed to answer this question in about 3,000 adults aged 65 to 79 but has not yet reported. Until it does, the honest answer is that the effect in healthy humans is unknown.

Is metformin anti aging medicine or a diabetes medicine?

Metformin is approved and prescribed as a medicine for type 2 diabetes, and is also used in selected adults at high risk of developing diabetes and, with weaker evidence, in polycystic ovary syndrome. It is not approved for aging anywhere in the world. Researchers are studying whether it might act on aging biology, but that remains a hypothesis under investigation rather than an established use.

Can a doctor prescribe metformin for non diabetics who want to live longer?

A doctor can legally prescribe metformin off-label, but most will not for longevity alone, because there is no randomized evidence of benefit in healthy people while the known side effects remain. Guidelines support metformin for diabetes and for high-risk prediabetes, where trials show it delays disease. Whether an individual qualifies for treatment depends on their metabolic test results and is a decision for the treating clinician.

Which organ is metformin hard on?

Metformin is hardest on the digestive tract in the first weeks, causing nausea, cramping or diarrhea in up to a quarter of people. It is not toxic to the kidneys or liver, but it is cleared by the kidneys, so if kidney function is poor the drug accumulates and the risk of a rare complication called lactic acidosis rises. That is why kidney tests are done before and during treatment.

Why do I feel so much better on metformin?

Most people who feel better on metformin had elevated blood sugar that was quietly causing fatigue, thirst and frequent urination. As glucose control improves over a few weeks, that burden lifts and energy returns. The drug also smooths appetite swings through its effects on the gut. People with normal blood sugar have no such burden to remove, and small studies in healthy volunteers do not report a comparable sense of wellbeing.

Do people on metformin look younger?

No human trial has measured whether metformin makes people look younger. A 2024 study in 12 elderly male monkeys found younger biological age scores in several tissues including skin, which is intriguing but not a human result. In people with diabetes, better glucose control reduces sugar damage to collagen, which may help skin over time, but that benefit comes from controlling blood sugar rather than from metformin specifically.

What are metformin side effects long term?

The main long-term effect is reduced vitamin B12 absorption, which can lead to deficiency causing numbness, tingling, fatigue, anemia and memory changes, so periodic B12 testing is recommended. Digestive symptoms usually ease after the first weeks. Lactic acidosis is rare and mostly tied to poor kidney function or acute illness. Metformin does not cause weight gain or low blood sugar on its own and has a favorable heart safety record.

Can you stay on metformin for life?

Many people with type 2 diabetes take metformin for decades, and there is no inherent time limit. What determines whether it continues is kidney function, which is checked regularly and declines with age. Guidelines set thresholds at which the medicine is reduced or stopped. It is also paused temporarily around surgery, contrast scans or serious illness. For people without diabetes, no study has examined lifelong use.

Does metformin reduce cancer risk?

Early observational studies suggested lower cancer rates among metformin users, but randomized trials have not confirmed a benefit. A large trial adding metformin to standard breast cancer treatment, reported in 2022, found no improvement in cancer outcomes. The earlier observational signal probably reflected differences in who gets prescribed metformin rather than a protective effect of the drug itself.

What is the TAME trial and when will it report?

TAME, or Targeting Aging with Metformin, is a planned randomized trial of about 3,000 adults aged 65 to 79 without diabetes, followed for roughly six years to see whether metformin delays a composite of age-related diseases including heart disease, cancer, dementia and death. Regulators agreed to this novel endpoint in 2016. As of early 2026 enrollment is incomplete because funding has lagged, so no results date exists.

References

• Metformin: MedlinePlus Drug Information
• Metformin: a medicine to treat type 2 diabetes (NHS)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.